Accendra Health vs Quanome Technologies
Accendra Health reported revenue of $2.8 billion in fiscal 2025, 468.1 times Quanome Technologies' $6 million in fiscal 2026. Accendra Health's revenue grew 3.1% in its latest year, and Quanome Technologies' grew 111.8%. Accendra Health had an operating margin of 1.0%, against -174.2% at Quanome Technologies. Free cash flow was −$293 million at Accendra Health and −$3 million at Quanome Technologies. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Accendra Health | Quanome Technologies | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $2.8B | $6M |
| Revenue growth | 3.1% | 111.8% |
| Revenue growth a year, last 5 years | −20.1% | — |
| Gross margin | 46.7% | 56.7% |
| Operating margin | 1.0% | −174.2% |
| Net margin | −39.9% | −162.1% |
| Free cash flow | −$293M | −$3M |
| Free cash flow margin | −10.6% | −54.5% |
| Return on capital | 1.2% | — |
| Net debt to EBITDA | 7.3x | — |
| Dividends and buybacks | $10M | $0M |
| Change in diluted share count | 0.2% | 240.3% |
| Last close | $0.09 | $0.27 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $4,046 | — |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Accendra HealthQuanome Technologies
Operating margin
Percent of revenue
Accendra HealthQuanome Technologies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Accendra HealthQuanome Technologies
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Accendra Health and Quanome Technologies pages.